NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $15.03 +2.31 (+18.16%) Closing price 04:00 PM EasternExtended Trading$15.06 +0.03 (+0.17%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GH Research Stock (NASDAQ:GHRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GH Research alerts:Sign Up Key Stats Today's Range$12.72▼$15.3350-Day Range$9.00▼$13.7952-Week Range$6.00▼$20.50Volume411,150 shsAverage Volume196,014 shsMarket Capitalization$782.01 millionP/E RatioN/ADividend YieldN/APrice Target$32.00Consensus RatingBuy Company Overview GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Read More GH Research Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 38% of companies evaluated by MarketBeat, and ranked 804th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 4 research reports in the past 90 days.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.05) per share.Price to Book Value per Share RatioGH Research has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.98% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently decreased by 3.50%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.98% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently decreased by 3.50%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.80 News SentimentGH Research has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GH Research this week, compared to 3 articles on an average week.Search Interest2 people have searched for GHRS on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address GHRS Stock News HeadlinesTD Cowen Sticks to Its Buy Rating for GH Research (GHRS)June 27, 2025 | theglobeandmail.comJMP Securities Reaffirms "Market Outperform" Rating for GH Research (NASDAQ:GHRS)June 26, 2025 | americanbankingnews.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 2 at 2:00 AM | Paradigm Press (Ad)GH Research Submits IND Hold Response to FDAJune 20, 2025 | tipranks.comGH Research Submits Complete IND Hold Response to FDA Ahead of ScheduleJune 20, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight RatingJune 5, 2025 | insidermonkey.comGH Research to Present at ASCP Meeting on Breakthrough Depression TreatmentMay 27, 2025 | tipranks.comGH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual MeetingMay 15, 2025 | globenewswire.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $7.00 at the beginning of 2025. Since then, GHRS stock has increased by 114.7% and is now trading at $15.03. View the best growth stocks for 2025 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.42. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol Myers Squibb (BMY), Zoom Communications (ZM), atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings5/08/2025Today7/02/2025Next Earnings (Estimated)9/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$25.00 Potential Upside/Downside+110.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-19.20% Return on Assets-18.40% Debt Debt-to-Equity RatioN/A Current Ratio29.71 Quick Ratio29.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book4.41Miscellaneous Outstanding Shares52,030,000Free FloatN/AMarket Cap$789.35 million OptionableOptionable Beta0.96 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:GHRS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts